Pages

Showing posts with label Moderna. Show all posts
Showing posts with label Moderna. Show all posts

Tuesday, December 7, 2021

World scared about the current vaccines on Omicron why? an expert reviews....

The potential for rapid mutation of the new variant of the Covid-19 virus, Omicron, has alarmed the whole world. This new variant is being said to be more dangerous than Delta, which devastated the whole world a few months ago because so far 50 mutations have occurred in Omicron. Due to Omicron's ability to mutate very rapidly, the question is also being raised whether the current corona vaccine will be effective on this new variant? 

Meanwhile, British company Moderna has said that the current vaccine is likely to be less effective against Omicron. Why might existing vaccines be ineffective on Omicron? Omicron is said to be the fastest mutation virus ever. WHO has placed it in the category of “Variant of Concern”. There have been 33 mutations in its spike protein itself. 

Actually, it is through the spike protein that the virus opens the way to enter human cells. The vaccine prepares the body to fight against it by producing antibodies against the spike protein itself. More mutations in Omicron's spike protein have raised concerns about how effective current vaccines will be against it? The current vaccine has been designed according to the original coronavirus strain that surfaced in Wuhan, China, while Omicron's strain is completely different from it. This is the reason why this new variant of the existing vaccine is expected to have little or no effect.  

British company Moderna has said that the current vaccine against Omicron is expected to be less effective, amid discussions about the ineffectiveness of the vaccine against Corona's new variant Omicron. Moderna CEO Stephen Bensel told the Financial Times that current vaccines may be less effective against Omicron than earlier strains of the corona. Bensal also warned that it could take months for pharmaceutical companies to manufacture large-scale vaccine doses against the new variant. Omicron's potential for sharp mutations in the spike protein may require pharma companies to modify existing vaccines next year, he said. 

Amidst the discussion on Omicron about the less effective or completely ineffectiveness of the existing vaccine, talk of bringing a new vaccine for it has started. British company Moderna has said that if needed, the vaccine of this new variant can come in the early months of 2022. Moderna has already made an mRNA vaccine of Corona. Moderna's chief medical officer, Paul Burton, has said his company could launch an mRNA vaccine to combat Omicron early next year if needed. At the same time, Pfizer, another company that makes the corona vaccine, has said that if needed, it can make a new vaccine against Omicron in six weeks and make its initial dose available within 100 days. 

The World Health Organization (WHO) has so far approved the use of a total of eight corona vaccines worldwide. These eight vaccines currently being used for corona can be divided into three categories. One is the messenger RNA vaccine, the other is the viral vector vaccine and the third is the inactivated vaccine. The way these vaccines are made and work are different.  

Messenger RNA (mRNA) Vaccines: These vaccines contain messenger RNA (mRNA) codes, which go into the body to make a version of the coronavirus protein. After vaccination, your immune cells begin to make fragments of the spike protein, and your body starts making antibodies. If you are later infected with the COVID-19 virus, these antibodies help fight against the virus. 

Viral vector vaccine: This is a carrier vaccine, in which a non-harmful adenovirus is genetically engineered as a viral vector. When this virus reaches our cells, it instructs them to make copies of this spike protein. As spike proteins build up on the surfaces of your cells, your immune system responds by making antibodies and defensive white cells. When infected with the coronavirus, these antibodies are used to fight the virus. 

Inactivated Vaccine: A dead or inactivated virus is used in this. This inactivated virus can neither multiply nor make you sick. Through this vaccine, an immune response is prepared in the body similar to a natural infection.

Stay healthy, stay safe...

 

Monday, September 27, 2021

COVID-19 Vaccines have good future in treatment of Cancer patients.........

"Covishield, Moderna, and Pfizer vaccines are found effective in the treatment of cancer disease, research revealed"

The effective vaccine to prevent corona is also proving good effect on cancer patients without showing any side effects on the patients. Scientists have presented their research at the conference of the European Society of Medical Oncology. 


A
ccording to the researchers, a suitable and protective immune response to the vaccine has been seen in cancer patients. According to the study, the third booster dose of the vaccine may prove to be more effective in cancer patients. Researchers also presented several previous studies and reports published in journals showing the effective effect of Covid -19 on cancer patients.

Vaccine develops effective immunity on cancer patients- Clinical trials of these vaccines were not done on cancer patients, because during the treatment of cancer, the immunity of the patients is already low due to the disease, so there was a fear about whether the vaccine is safe for the patients or not. Clinical trials were not conducted on these patients. An earlier study explored the potential impact of chemotherapy and immunotherapy on the protection provided by vaccination against COVID-19. In the latest study, it has been proved that the vaccine develops effective immunity against Covid in cancer patients.

Sufficient levels of antibodies found in cancer patients- Researchers included several hundred patients from different hospitals in the Netherlands in four different study groups to measure their responses to Moderna's two-dose vaccine. To validate the study, the researchers included non-cancerous individuals, patients treated with immunotherapy, patients treated with chemotherapy, and patients treated with a chemo-immunotherapy combination.

According to the study, after 28 days of giving the second dose, 84 percent of the patients receiving chemotherapy were found to develop sufficient antibodies against the corona. In addition, adequate levels of antibodies were also observed in 89 percent of patients receiving chemo-immunotherapy and 93 percent of patients receiving immunotherapy.

Male Infertility: Causes, Impact, and Consequences for Nations

Abstract: Male infertility is a complex and multifactorial issue that has profound implications not only for individuals and couples but al...